Biotech VC Funds

Arkitekt Ventures is a New York-based venture capital firm focused on advancing human health through early-stage investments. Their portfolio emphasizes innovative healthcare solutions, including digital health platforms, biotech, and frontier technologies like neurotech, AI, and bioengineering. Notable recent investments include Sollis Health, Nanite, and Mural Health, with check sizes ranging from $3M to $15M. Arkitekt primarily invests in the U.S. but has also backed companies in the UK, maintaining a sector focus in healthtech, medical devices, and life sciences. Their strategy centers on pre-seed to Series A stages, preferring startups with groundbreaking approaches to healthcare delivery and precision medicine. They rarely lead rounds but frequently co-invest with prominent partners like Bessemer Venture Partners and Torch Capital. Led by managing director Enke Bashllari and partner Pavan Choksi, Arkitekt Ventures values long-term partnerships and tends to back visionary founders who are leveraging cutting-edge science. Their team prefers a data-driven, relationship-building approach, and startups seeking funding should ideally present transformative technologies with strong early traction.

Artesian Investments, founded in 2004 by Jeremy Colless, Matthew Clunies-Ross, and John McCartney, is a global alternative investment management firm specializing in venture capital, public and private debt, and impact investment strategies. Based in Sydney, the firm has expanded its reach with offices in Melbourne, Adelaide, Shanghai, Jakarta, Singapore, London, and New York​​. Artesian's notable investments include Instaclustr, PouchNATION, and Regrow Ag. They are particularly active in the Asia-Pacific region, managing over $1.22 billion in assets and boasting more than 600 startup investments​ (Artesian)​. Their investment strategy focuses on early-stage ventures across various sectors, including technology, agrifood, medtech, and AI. Artesian also offers a unique "Venture Capital as a Service" (VCaaS) platform, providing customized investment solutions to corporations, government, and family offices​. The firm places a strong emphasis on ESG (Environmental, Social, and Governance) criteria and impact investing, aiming to deliver sustainable returns while addressing critical global challenges. Artesian is a certified B Corp, underscoring their commitment to positive social and environmental impact. Key team members include Jeremy Colless (CEO), Matthew Clunies-Ross (CIO), and Luke Fay (Partner, Australian Venture Capital). Their diversified team spans multiple continents, bringing extensive expertise and a global perspective to their investment activities

Artiman Ventures, founded in 2001, is a venture capital firm based in Silicon Valley with an additional office in Bangalore. The firm specializes in early-stage investments and adopts a "white space" investment strategy, focusing on sectors with little to no existing competition, thereby seeking to create or disrupt multi-billion dollar markets. Artiman is sector-agnostic and invests across a diverse range of industries including technology, medtech, and communications. Notable investments in Artiman's portfolio include companies like Virsec, which focuses on application security, and Visby Medical, which is revolutionizing disease diagnostics. Other significant investments include ApplyBoard, an AI-enabled marketplace for international students, and CellMax Life, a precision cancer blood-testing company. Geographically, Artiman primarily invests in companies based in the U.S. and India, leveraging its cross-border presence to help startups scale globally. Their investment strategy involves being the first institutional capital, often at the concept phase, and working closely with entrepreneurs to drive strategy, market definition, and execution​. The leadership team at Artiman includes experienced partners like Yatin Mundkur, Amit Shah, and Ajit Singh, who bring deep expertise in technology and life sciences investments. Founder Eric Benhamou, known for his tenure as CEO of 3Com and Palm, leads the team with a strong background in growing and managing tech companies.

ARTIS Ventures (AV) is a San Francisco-based venture capital firm founded in 2001 by Stuart Peterson, investing in category-defining companies at the intersection of technology, health, and biology. The firm coined and trademarked the term TechBio to describe this investment category, and has built one of the most distinctive track records in the space over more than two decades. Peterson is a Forbes Midas List honoree, recognized in large part for ARTIS's early bet on Stemcentrx. Additional partners include Austin Walne and Ameena El-Bibany. ARTIS leads rounds and deploys $250K to $25 million per investment — with a sweet spot around $10 million — at Seed and Series A stages across the United States, Canada, and Israel. With 84 investments to date, the portfolio spans YouTube, Palantir, Data Domain, Aruba Wireless Networks, Nimble Storage, Cohesity, Practice Fusion, Versa Networks, Excision BioTherapeutics, and Fabric Genomics. The firm invests across biotech, AI, software, health technology, and data analytics. ARTIS runs a structured TechBio Fellows program that embeds MDs, PhDs, and domain experts directly within the fund to work alongside the investment team and portfolio companies. This model bridges frontier science and venture investing in a concrete way: rather than relying on external advisors, the firm has built its own scientific talent pipeline inside the fund. The result is a portfolio company support infrastructure that is unusually deep for a venture firm of ARTIS's size.

Asahi Kasei Ventures — formally Asahi Kasei Corporate Venture Capital — is the CVC arm of Asahi Kasei Corporation, a diversified Japanese conglomerate with revenues exceeding $20 billion across its Materials, Homes, and Health Care divisions. Established in 2008 in Tokyo and operating from Silicon Valley since 2011, with additional offices in Menlo Park and Boston, the fund invests in innovative startups strategically aligned with Asahi Kasei's long-term business development. General Manager Takashi Morishita has guided the fund since inception, personally involved in investments in 30-plus startups. The firm has invested in 53-plus companies across the United States, Europe, China, and Japan, averaging two new investments annually. Checks range from $1 million to $10 million at seed through Series B stages. Focus areas include healthcare and digital health, advanced materials, IoT, clean technology, energy storage, hydrogen, and biopharmaceuticals. The most recent investment was in Glycomine at Series C in April 2025. The fund's Care for Earth investment framework extends the mandate to environmental startups in sustainability and carbon neutrality. Portfolio companies gain access to Asahi Kasei's extensive research capabilities, manufacturing infrastructure, and global commercial network — advantages that have resulted in multiple strategic collaborations and two acquisitions for the parent company. The fund's long-term orientation and corporate backing allow it to support companies through extended development cycles that financial-only investors may not sustain.

Ascension Ventures is a strategic healthcare-focused venture capital firm based in St. Louis, Missouri. Launched in 2001 by Ascension, it manages over $1 billion in assets across five funds. The firm strategically invests in early to late-stage companies within healthcare services, health technology, and medical devices. Its unique approach connects more than 450 healthcare providers, creating an ecosystem that enables startups to directly engage with health system executives, driving solutions that address complex healthcare challenges. Ascension Ventures’ portfolio includes companies like Olive (an AI platform for healthcare administration), EBR Systems, and GetWellNetwork, reflecting its emphasis on technology that enhances clinical outcomes, patient experience, and operational efficiency. The firm typically invests between Series A and B rounds, with capital sizes ranging from $10 to $20 million per company, often seeking board seats or observer rights to guide their portfolio firms. The firm is distinguished by its close ties to 13 major health systems, which represent a network of over 580,000 healthcare professionals. This strategic positioning allows Ascension Ventures not only to provide funding but also to facilitate partnerships and scale innovations that improve healthcare delivery across the United States.

Aspect Ventures, founded in 2014 by Jennifer Fonstad and Theresia Gouw, is a leading venture capital firm based in Palo Alto, California. The firm focuses on early-stage investments, primarily in Series A rounds, across various sectors including cybersecurity, fintech, digital health, and enterprise software. Notable investments include Gusto, a cloud-based HR management platform; Chime, a digital bank; and Exabeam, a cybersecurity company. Aspect Ventures has had several successful exits such as Forescout Technologies, Imperva, and Trulia.

Asset Management Ventures (AMV) is a Palo Alto-based venture capital firm founded in 1965 by Pitch Johnson, one of Amgen's co-founders — making it one of the longest continuously operating VC firms in Silicon Valley. The firm specializes in early-stage investments in digital health, technology, and life sciences, and raised its fifth and largest fund at $150 million in 2020. Partners Skip Fleshman and Lou Lange lead the current investment team, which combines scientific, engineering, and medical expertise with decades of investing experience. With 152 investments and 29 exits, AMV's historical portfolio includes Amgen itself, Tandem Computer, and Applied BioSystems — foundational companies in their respective industries. The current portfolio includes Reify Health, Evidation Health, Lark, Twist Bioscience (TWST), Freenome, Welldoc, ViewPoint Therapeutics, Aavia, and 3T Biosciences, reflecting AMV's sustained focus on health technology and life sciences innovation. The firm leads rounds and deploys $1 million to $15 million across seed through Series B stages. AMV's six-decade track record is its most distinctive asset: the firm has seen multiple complete technology and healthcare cycles, giving the investment team a depth of pattern recognition and investor network that newer funds cannot replicate. The founding connection to Amgen also provides an ongoing cultural orientation toward building enduring life sciences companies rather than optimizing for short-cycle exits — an orientation that informs how AMV partners with founders over the long arc of company development.

Astanor Ventures, founded in 2017 by Eric Archambeau and George Coelho, is a Brussels-based venture capital firm specializing in sustainable agrifood technologies. The firm focuses on investing in early-stage, mission-driven companies that address significant social or environmental issues within the agrifood value chain. This includes sectors like regenerative agriculture, bioeconomy, and climate-positive solutions. Astanor recently closed its second venture fund at €360 million, bringing its total assets under management to €800 million. This fund will support innovative solutions aimed at transforming the global food system to be more sustainable and resilient​. The firm boasts an extensive network of entrepreneurs, experts, scientists, and policymakers, which helps identify and nurture groundbreaking technologies. Notable investments include companies that advance autonomous electric agricultural machinery, high-functioning proteins, and genomic sequencing for sustainable food production.

Astarc Ventures, established in 2015, is the corporate venture arm of Astarc Group based in Mumbai, India. The fund focuses on early-stage investments in innovative technology companies across various sectors, including fintech, healthtech, logistics, AI/ML, and e-commerce. Notably, Astarc Ventures invests globally, with a presence in markets like India, Israel, the United States, and the United Kingdom. The firm typically supports entrepreneurs whose ventures align with Astarc Group's strategic interests and disruptive technologies. With over 60 investments, Astarc Ventures has backed companies such as Rooter, Purple Style Labs, Jai Kisan, and Dataloop. These investments span diverse industries from AI-driven solutions to consumer marketplaces and climate-tech. The firm is also known for its exits, including Liv.ai, which was acquired by Flipkart in 2018. Led by Executive Director Salil Musale and an experienced team, Astarc Ventures leverages deep operational expertise to help portfolio companies scale. The team takes an active role in guiding startups, offering both strategic advice and operational support, especially in emerging sectors.

Astarte Ventures is a Yardley, Pennsylvania-based venture capital fund founded in 2013 by Tracy Warren, recognized as the first venture fund dedicated exclusively to the health and wellbeing of women and children. As a first-mover in FemTech investing — well before the category had a name — Warren built a concentrated portfolio anchored in early intervention and prevention, spanning healthtech, life sciences, and technology sectors that improve outcomes for mothers, women, and children. Warren also serves as a mentor at Harvard's Wyss Institute. The fund has made eight investments at seed and Series A stages with checks of $500K to $3 million. Two outcomes define the portfolio's credibility: Maven Clinic, which became the largest virtual clinic for women's and family health and achieved unicorn status in 2021, and Alydia Health, acquired by Organon for $215 million in March 2021. These exits anchor the fund's FemTech track record against a backdrop of concentrated, conviction-led investing. Astarte Ventures' small portfolio size is intentional — Warren's model prioritizes deep engagement with each company over broad deployment. Each portfolio company benefits from Tracy Warren's domain expertise in female health outcomes and impact investing, as well as her network across academic medicine, women's health advocacy, and the broader healthcare industry. For founders in FemTech, backing from Astarte carries the credibility of the category's earliest and most dedicated institutional champion.

Astellas Venture Management (AVM) is the wholly-owned corporate venture capital arm of Astellas Pharma, one of the world's leading pharmaceutical companies. Founded in 2005 and headquartered in South San Francisco, AVM has provided equity investments to private, early-stage companies developing therapeutic programs and platform technologies for over twenty years. The investment thesis is explicitly strategic: AVM targets science that enhances the Astellas R&D pipeline or catalyzes new directions in discovery research, with the team's Pharma View serving as both a selection lens and a support framework. AVM has invested in 61 companies across 104 total investment rounds, deploying $3 million to $20 million per company at seed through Series B stages. Series A is the most active stage, with 19 investments averaging $33.8 million in round size. Notable current portfolio companies include Solu Therapeutics, Syntax Bio, PhoreMost, and Somite. The most recent investment was in Solu Therapeutics in April 2025, and the most recent exit was Orna Therapeutics in February 2026. A team of eight, including three partners and one principal, spans the US and Japan. AVM's principal value to portfolio companies is its deep pharmaceutical industry expertise and the pathway it opens to Astellas Pharma: strategic licensing dialogues, research collaborations, and potential acquisitions that purely financial investors cannot facilitate. For early-stage biotech founders, AVM's Pharma View means receiving guidance from investors who understand drug development not as outsiders but as participants in the global pharmaceutical system.

Aster Capital, established in 2000 and based in Paris, is a venture capital firm specializing in Climate Tech investments. The firm focuses on sectors such as energy, mobility, and industry, supporting startups at various stages of development. Aster Capital manages around €500 million in assets and operates globally with offices in Paris, San Francisco, and Tel Aviv. Key investments by Aster include companies like ekWateur, an energy supplier accelerating the energy transition; Betterway, a pioneer in employee mobility solutions; and Iceotope, specializing in liquid cooling technologies for data centers. These investments reflect Aster’s commitment to supporting innovative solutions that contribute to carbon neutrality. Aster recently raised €240 million to invest in energy transition and future mobility projects, underscoring their dedication to driving significant environmental impact through technology. The firm’s strategy involves not only financial investment but also providing extensive support through their "Business Hub" approach, which facilitates business opportunities and partnerships for their portfolio companies​.

AstraZeneca is a leading global biopharmaceutical company with a strong focus on oncology, biopharmaceuticals, and rare diseases. They are committed to discovering, developing, and delivering innovative medicines that transform the lives of patients worldwide. AstraZeneca's oncology portfolio is particularly noteworthy, with a significant emphasis on creating groundbreaking cancer treatments. Their strategy includes leveraging various scientific platforms such as antibody-drug conjugates (ADCs), radioconjugates, and T cell engagers. Recent high-profile deals include collaborations with Daiichi Sankyo for ADCs and the acquisition of Neogene Therapeutics to enhance their T cell receptor therapy capabilities​​. In addition to oncology, AstraZeneca has a robust pipeline in biopharmaceuticals aimed at addressing chronic diseases and enhancing long-term health outcomes. They are also advancing treatments for rare diseases, expanding their reach globally to ensure broader access to their innovative therapies​​. AstraZeneca's business development approach is integral to their growth, focusing on strategic alliances and partnerships. This includes collaborations with companies like Tempus for AI-enabled precision medicine and various biotech firms to accelerate advancements in areas like epigenetics and undruggable targets​​. The company emphasizes a culture of innovation, diversity, and sustainability, aiming to make a significant impact on global health while maintaining environmental responsibility through initiatives like Ambition Zero Carbon​.

Asymmetry Ventures, based in San Francisco, is a prominent early-stage venture capital firm founded by Rob Ness. The firm focuses on investing in transformative startups that have the potential to create significant impact. They have a diverse portfolio of over 280 investments, including notable companies like BillionToOne, Foresight Mental Health, Mast Reforestation (formerly DroneSeed), and Orbit Fab. Asymmetry Ventures is known for their commitment to supporting defensible businesses, particularly in sectors such as artificial intelligence, biotechnology, and aerospace. They typically make initial investments in the range of $2 million and have been involved in notable funding rounds such as Orbit Fab's $10 million raise, which also saw participation from major aerospace players like Northrop Grumman and Lockheed Martin. The firm prides itself on identifying and backing visionary founders and innovative business models, with a strong emphasis on early-stage investments that leverage technology to create natural barriers to entry and generate recurring revenue streams. They also prioritize investments that address significant market needs with scalable solutions. For startups looking to partner with Asymmetry Ventures, demonstrating a strong leadership team and a clear path to market dominance are crucial. The firm's deep network and extensive industry experience provide valuable support and guidance to their portfolio companies, enhancing their potential for growth and success.

At One Ventures is a venture capital firm founded in 2020 by Tom Chi, a founding member of Google X. The firm is dedicated to investing in early-stage startups that are developing disruptive deep tech solutions aimed at making humanity a net positive to nature. With a strong focus on climate tech, At One Ventures has established itself as a significant player in the industry. The firm recently closed its second fund at $375 million, indicating strong investor confidence and a robust commitment to supporting climate-positive innovations. This fund follows their initial $150 million fund and aims to support startups that can dramatically reduce environmental footprints while upending established industrial economics. At One Ventures' investment portfolio includes companies across various sectors such as renewable energy, sustainable agriculture, and advanced materials. Notable investments include Noon Energy, which focuses on long-duration energy storage, and MightyFly, which is developing hybrid electric drone delivery systems. The firm's approach is hands-on, providing strategic guidance in talent acquisition, operations, marketing, IP strategy, and manufacturing. The team at At One Ventures consists of experienced professionals with backgrounds in physical sciences, engineering, manufacturing, and finance, ensuring a deep understanding of the technologies and markets they invest in. They operate globally, with a presence in San Francisco and London, and continue to seek partnerships with entrepreneurs, scientists, and investors who share their vision for a sustainable future.

Ataraxia VC is a global venture capital firm managing multiple funds, including the Social Starts and Joyance Partners funds, which focus on early-stage investments in health, happiness, and well-being. Ataraxia typically operates at the pre-seed and seed stages, with follow-on investments up to Series A. They target sectors like biotech, neuroscience, precision health, femtech, and next-gen food technologies. Their portfolio includes over 250 companies globally, with a strong focus on science-driven, transformative opportunities. The firm's strategy emphasizes investments in innovative companies that align with its vision of improving health and happiness through technology. With funds spread across the US and Europe, Ataraxia provides both capital and strategic guidance to help startups scale rapidly. They prioritize founders with groundbreaking solutions, especially in consumer tech, wellness, and sustainability-focused sectors. Key team members include Mike Edelhart, a seasoned investor with decades of experience, and Holly Jacobus, an investment partner with a focus on femtech, farmtech, and sustainable manufacturing. Ataraxia’s approach is hands-on, often providing mentorship and guidance through every stage of a startup’s journey​.

Atento Capital is a Tulsa-based venture capital firm founded with the mission of supporting early-stage tech startups, particularly those in underinvested communities. The firm was launched with backing from the George Kaiser Family Foundation, focusing on generating both market returns and social impact by funding innovative companies in the Heartland region of the U.S. Atento primarily invests in seed and early-stage companies, with check sizes ranging from $250,000 to $3 million. They are committed to fostering diversity in entrepreneurship, directing nearly half of their capital to underrepresented founders, including women and founders of color. Notable portfolio companies include RobbieAI, a platform using computer vision to prevent patient injuries, and PatchRx, a health tech solution aimed at improving medication adherence​. Beyond funding, Atento provides hands-on support to startups by offering mentorship, business development guidance, and access to local talent via partnerships with organizations like inTulsa. Their approach is deeply rooted in building long-term success for founders who have traditionally been overlooked by the broader venture capital ecosystem.

Atinum Investment, the venture capital arm of Atinum Partners, is a prominent South Korean investment firm with over $450 million in assets under management. The firm focuses on diverse sectors such as deep tech, artificial intelligence, blockchain, advanced robotics, bio-healthcare, and IT components. They actively invest in early-stage to growth-stage startups with significant global market potential. Notable portfolio companies include CryptoQuant, Allganize, and Klook. Atinum Investment has a global reach, particularly focusing on Southeast Asia, with investments in companies like InstaReM and Fast Five, a South Korean co-working space startup. The team at Atinum Investment includes key figures such as Wan Gee Cho, who specializes in deep tech and SaaS investments, and Peter Na, the Regional Head for Southeast Asia, focusing on investments in the region from the Singapore office. Atinum is committed to providing more than just capital by offering strategic guidance and opening doors to potential customers and partners, ensuring the growth and success of their portfolio companies.

Atlantic Bridge, founded in 2004, is a global growth equity technology firm that focuses on investing in deep technology companies across Europe, the UK, and the US. With over €1 billion in assets under management, the firm has a portfolio of 70 companies and has created over 5,000 jobs. Atlantic Bridge is known for its cross-border value-add strategy, helping portfolio companies expand internationally through its offices in Dublin, London, Munich, Paris, and Palo Alto. The firm's portfolio includes notable companies such as SOC Prime, which specializes in enterprise threat detection and response, and Elisity, which combines Zero Trust Network Access with an AI-enabled Software Defined Perimeter. Other significant investments include Siren, an investigative intelligence platform, and Aizon, which optimizes pharmaceutical manufacturing processes using real-time data and predictive models. Atlantic Bridge has achieved successful exits with companies like Navitas Semiconductor, which recently debuted its GaN Power ICs on Nasdaq, and Mitiga, a provider of hybrid managed services for incident response and readiness. The firm is led by experienced industry professionals, including Managing Partners Elaine Coughlan, Brian Long, and Kevin Dillon, who bring extensive expertise in scaling technology companies and executing successful IPOs and M&As.

FoodLabs, founded in 2015 and based in Berlin, Germany, is a prominent venture capital firm dedicated to investing in innovative startups within the food, health, and sustainability sectors. The firm supports companies aiming to revolutionize how we produce, consume, and think about food, with a mission to create sustainable and healthy solutions for the future. FoodLabs has made a significant impact with its diverse portfolio, which includes companies like ChefCoco, a personalized weekly menu service, and Van Heron Labs, which focuses on biotechnology. The firm has been an early investor in some of the most influential European FoodTech startups, such as Infarm, Meatable, Mushlabs, and Sanity Group. These investments span across various stages, from pre-seed to series B and beyond, demonstrating FoodLabs' commitment to nurturing startups through their growth journey. The team at FoodLabs, led by founder Christophe Maire and managing director Patrick Noller, combines deep industry expertise with a strong network to provide strategic support and resources to their portfolio companies. They are particularly focused on sectors like synthetic biology, climate resilience, and health, aiming to address some of the world's most pressing challenges.

Atlantic Labs, based in Berlin, is a prominent early-stage venture capital firm that supports mission-driven founders across Europe. Founded in 2013, the firm has a focus on investing in transformative technology sectors such as climate tech, digital health, future of work, AI and data, industrial automation, mobility and logistics, fintech, and proptech. Atlantic Labs typically invests at the pre-seed stage, with investment sizes ranging from €25,000 to €5 million or more. They have backed over 215 companies, including notable names like SoundCloud, GetYourGuide, Clue, Vimcar, and Cazoo. The firm emphasizes a hands-on approach, providing not only capital but also strategic guidance and access to a robust network of industry experts to help their portfolio companies grow and succeed. The firm's portfolio reflects its diverse focus areas, supporting companies that aim to redefine various industries through innovative solutions. Examples include digital health companies like Clue, AI and data startups such as Mobius Labs, and mobility ventures like GetYourGuide and Cazoo. Atlantic Labs is led by a team of experienced investors and operators who are committed to supporting entrepreneurs throughout their entire journey. This commitment to fostering innovation and growth has established Atlantic Labs as a key player in the European venture capital landscape.

Atlas Venture is a leading biotech venture capital firm focused on creating and building innovative life science companies. With over 30 years of experience, they have incubated over 70 startups and taken 40 companies public, including Intellia Therapeutics, Kymera Therapeutics, and Generation Bio. Atlas specializes in drug discovery and development, emphasizing areas like gene editing, oncology, and immunotherapy. Headquartered in Cambridge, Massachusetts, Atlas primarily targets U.S.-based startups but maintains a global vision, partnering with top scientific minds. They invest early, often leading seed and Series A rounds, with typical check sizes ranging from $5M to $20M. Atlas's approach is hands-on, actively incubating new ventures and co-founding companies with a strong operational focus. Key figures include Jean-François Formela, who has been instrumental in several high-profile exits and IPOs, and focuses on cutting-edge drug discovery technologies. Founders approaching Atlas should focus on breakthrough science with clear therapeutic applications, as the firm seeks to translate groundbreaking research into life-changing medicines.

Atlas Venture is a leading venture capital firm specializing in early-stage investments in biotechnology and life sciences. Founded in 1980 and based in Cambridge, Massachusetts, Atlas Venture has built a robust portfolio by focusing on groundbreaking biotech innovations. The firm has raised multiple funds, including their most recent Fund XIII at $450 million, which emphasizes their commitment to fueling biotech startups from seed stage through to successful exits​. Notable investments in their portfolio include companies like Intellia Therapeutics, Kymera Therapeutics, and Ikena Oncology. These investments highlight Atlas Venture's dedication to developing therapies that address significant unmet medical needs, particularly in oncology and genetic disorders. Intellia Therapeutics, for instance, is renowned for its gene-editing technologies, while Kymera Therapeutics focuses on protein degradation to treat diseases. Atlas Venture has achieved numerous successful exits, such as the acquisitions of IFM Therapeutics by Bristol-Myers Squibb and Novartis, and the IPO of Generation Bio. These exits underscore the firm’s strategic capability in identifying and nurturing high-potential biotech startups to maturity. The firm is led by a team of experienced partners, including Jean-Francois Formela, Jason Rhodes, and David Grayzel, who bring a wealth of expertise in venture capital and life sciences. This team collaborates closely with entrepreneurs to provide not just capital but also strategic guidance and operational support, leveraging their extensive network within the biotech industry. For startups aiming to partner with Atlas Venture, it is crucial to present innovative solutions with strong scientific foundations and clear pathways to address significant medical challenges. The firm values startups that demonstrate potential for substantial clinical impact and scalability within the healthcare sector.

Atomico, founded in 2006 by Skype co-founder Niklas Zennström, is a leading venture capital firm based in London, with additional offices in Paris, Berlin, and Stockholm. The firm focuses on Series A and beyond investments in disruptive technology companies globally. Atomico's notable investments include Klarna, Truecaller, Lime, Hinge Health, and Rovio, which highlight their strong presence in fintech, healthcare, consumer tech, and gaming sectors. Atomico's investment strategy centers around partnering with mission-driven European founders, providing them with not just capital but also extensive operational support through their Growth Acceleration Team. This team assists with scaling operations, strategic planning, and navigating complex market dynamics. Their typical investment range is from $10 million to $50 million, and they often lead rounds, ensuring significant influence in their portfolio companies' trajectories. The firm is known for its diverse team and deep industry expertise. Key figures include Niklas Zennström, CEO and Partner; Chris Barnes, COO; and Thomas Wehmeier, Partner and Head of Insights, all based in London. This diverse leadership team brings a wealth of experience from various sectors, enhancing their ability to support and scale innovative startups. For startups looking to engage with Atomico, it's crucial to showcase innovative solutions with a potential for significant market impact. The firm is particularly interested in technology-driven companies that can leverage shifts in consumer behavior and technological advancements.

ATP Fund, established in 2014 and headquartered in Austin, Texas, is an early-stage venture capital firm that focuses on deep tech investments aimed at advancing human conditions through scientific innovation. The firm specializes in sectors such as artificial intelligence (AI), biotechnology, cleantech, cybersecurity, enterprise software, healthcare, and robotics. ATP Fund is known for its strategic investments in startups that are tackling some of the most challenging and impactful problems of our time. ATP Fund adopts a contrarian and hands-on approach, often partnering with scientific entrepreneurs at the earliest stages of their ventures, sometimes even at the formation stage via their Proto.n initiative. This strategy reflects their commitment to long-term partnerships and their belief in the transformative potential of cutting-edge technologies. The fund's portfolio includes a variety of high-impact companies like Diligent Robotics, which focuses on healthcare robotics, and Infleqtion, a firm that specializes in quantum technology. These investments highlight ATP Fund's dedication to supporting ventures that have the potential to make significant advancements in their respective fields. ATP Fund collaborates with a wide network of co-investors, including notable names like Texas Venture Labs and Osage University Partners. The firm has also seen successful exits, further establishing its reputation as a key player in the deep tech investment landscape.

Atria Ventures is a San Francisco-based venture capital firm founded in 2023 by General Partner Chris Leiter. The firm invests at the intersection of life sciences and artificial intelligence, partnering with founders working at the edges of biology and human health to reimagine the trillion-dollar life sciences industry from molecule to patient. Atria leads rounds at pre-seed and seed stages, with a sweet spot of $800,000 and a range of $250,000 to $2 million. Through its closed Fund I, Atria has made 15 investments across healthcare AI, biotech, and clinical development. Notable portfolio companies include Sleuth Insights in healthcare analytics, Peer AI in healthcare artificial intelligence, and Trially in clinical trials technology. The most recent investment was in Peer AI's Series A in October 2025, reflecting the firm's commitment to following its strongest portfolio companies into later rounds. Atria differentiates itself through singular focus on the convergence of computational approaches and life sciences — a sector where AI is fundamentally transforming drug discovery, diagnostics, clinical trials, and patient care delivery. Rather than investing broadly across healthcare, the firm concentrates on companies where deep learning, biological data, and clinical insight create compounding advantages. Chris Leiter's background informs a hands-on, thesis-driven approach that prioritizes founders working on problems with both scientific novelty and clear paths to clinical or commercial adoption.

Augment Ventures is a venture capital firm based in Ann Arbor, Michigan, specializing in early-stage investments across North America. The firm, founded in 2011 by Sonali Vijayavargiya, focuses on companies at the intersection of digital innovation and data utilization, particularly in sectors such as supply chain, fintech, industry 4.0, health tech, proptech, climate tech, B2B, and SaaS​. Notable investments by Augment Ventures include companies like LLamasoft, which was sold to Coupa Software for $1.5 billion, Optilogic, a cloud-native supply chain software solution, and Fluree, a platform recognized among the coolest data management companies​. Their portfolio also features innovative companies like Pair Team, Secro, Guardhat, and Crowdz, which span diverse industries from healthcare and fintech to supply chain and industrial safety. Augment Ventures emphasizes partnering with mission-oriented founders and diverse teams to address significant, real-world challenges. They provide not just capital but also strategic guidance and operational support to help startups scale and succeed in a constantly evolving global economy​.

Auriga Partners is a Paris-based venture capital firm established in 1998. The firm specializes in early-stage investments across various sectors, including information technology, life sciences, and cybersecurity. Auriga Partners has a strong focus on supporting high-potential ventures in Europe, North America, and Israel. Notable investments by Auriga Partners include Vade Secure, Nexthink, and Exeliom Biosciences. Vade Secure, a leader in predictive email defense, and Nexthink, a prominent analytics software provider, highlight Auriga’s commitment to backing innovative tech companies. Exeliom Biosciences, a biotech firm focused on the development of microbiome therapeutics, demonstrates their investment in life sciences. Auriga Partners has a robust portfolio with over 171 investments and 77 exits, reflecting their extensive experience and successful track record in venture capital. Their approach involves not only providing capital but also leveraging their expertise and network to support the growth and development of their portfolio companies. The team at Auriga Partners includes seasoned professionals like Philippe Granger, Mathieu Chatain, and Nabil Gharios, who bring significant industry knowledge and investment experience.

Aurum Ventures M.K.I is a Ramat Gan, Israel-based growth capital firm founded in 2005 as the venture capital vehicle of Morris Kahn, the prominent Israeli businessman and philanthropist who served as former chairman of Amdocs. The firm provides value-added capital to exceptional entrepreneurs in life sciences and clean technology, investing primarily at Series A, B, and later stages in companies with demonstrated clinical or commercial traction. Aurum has invested in 15 companies across biotech, clean tech, health technology, and pharma, with notable portfolio companies including LifeBond, Nephera, and BPT. The firm leads rounds with checks typically between $3 million and $20 million. Over its history, 55 co-investors have participated in Aurum's portfolio companies, including institutional names such as TELUS Ventures, RA Capital Management, and BlackRock — a reflection of the caliber of deal flow the firm sources. Aurum Ventures' core competitive advantage is the network, credibility, and industry relationships that come with the backing of Morris Kahn — one of Israel's most respected business leaders. Portfolio companies benefit from strategic guidance grounded in decades of operating and investing experience in the Israeli and global technology landscape. The firm's focus on life sciences and clean tech positions it at the intersection of two sectors where Israel has developed notable scientific and engineering depth, and where patient, relationship-driven capital creates meaningful differentiation at growth stage.

Autochrome Ventures is a Los Angeles-based inception and seed stage venture capital fund founded in 2016 by Vaughn Blake, who also leads Autochrome Capital Management. The firm invests in the technology sector with a particular emphasis on applied frontier and emerging technologies — areas where advances in science and engineering are being translated into new markets and business models. Autochrome engages at the earliest stages of company formation, often before conventional product milestones exist. The firm has built a portfolio of 21 companies across AI and deep tech, biotech, software, and clean technology, with checks ranging from $100,000 to $1 million. A notable portfolio investment is Tropic Biosciences, an agricultural biotech company, reflecting the fund's appetite for technically complex, science-driven ventures. Autochrome's last recorded investment was in April 2020, suggesting the fund has been in a harvesting or transitional phase. Autochrome differentiates itself through a willingness to engage before a company has fully taken shape — funding founders at the inception stage when capital is scarce and direction is still being established. Based in the Los Angeles technology ecosystem, the firm provides early-stage founders with capital and strategic guidance during the most formative period of company building. Its focus on frontier technology applications — spanning machine learning, biotech, and clean energy — reflects a thesis that the most significant value creation happens at the earliest intersection of emerging science and entrepreneurial ambition.

AV8 Ventures is a venture capital firm with a focus on early-stage investments in technology and healthcare sectors. Founded by George Ugras, who brings extensive experience from IBM Ventures and Apax Partners, AV8 Ventures operates primarily from Palo Alto and London. The firm leverages its deep expertise in applied AI, cloud computing, and big data to support transformative startups in these fields. The firm's investment strategy centers on identifying high-potential startups and providing them with not only capital but also strategic support and industry connections. AV8 Ventures emphasizes building long-term relationships with its portfolio companies, helping them scale and succeed in competitive markets. Notable investments by AV8 Ventures include companies like GrayMatter, which develops smart robotic solutions for manufacturing, and Precision Neuroscience, focusing on groundbreaking brain technology. These investments highlight AV8's commitment to supporting innovative technologies that address significant challenges in their respective industries. The team at AV8 Ventures, led by Ugras, comprises experienced professionals with backgrounds in venture capital, entrepreneurship, and technology development. This diverse expertise enables AV8 to provide comprehensive support to its portfolio companies, guiding them through various stages of growth and development. For startups looking to partner with AV8 Ventures, it’s essential to demonstrate strong technological foundations, clear market potential, and a vision for scalability and impact in the technology or healthcare sectors​.

Avalancha Ventures is a venture capital firm based in Mexico City, founded in 2015 by Lorenzo Garza and Rodrigo Ocejo. The firm focuses on early-stage investments, typically ranging from $50,000 to $300,000, with the potential for follow-on investments up to $2,000,000. Avalancha Ventures aims to support technology-driven companies that disrupt their target markets and show significant growth potential. Their portfolio includes notable investments such as Bind ERP, a cloud-based ERP platform for Mexican SMBs, and Syncfy, an open finance platform in Latin America. Other significant investments include Appaguitos.com, Bridgefy, WIHOM Software, and Carryt. These investments span across various industries including fintech, telecommunications, software, logistics, and e-commerce​. Avalancha Ventures is committed to helping its portfolio companies navigate their growth journeys, offering not just capital but also strategic support and expertise to help them scale and succeed in competitive markets.

Avalon BioVentures, based in La Jolla, California, is a leading venture capital firm dedicated to early-stage biomedical innovation. With a $135 million fund, ABV1, Avalon BioVentures continues the legacy of Avalon Ventures by focusing exclusively on life sciences. Notable investments include Vertex Pharmaceuticals, Onyx Pharmaceuticals, Amira Pharmaceuticals, and Neurocrine Biosciences. More recent successes include Sitari Pharmaceuticals (acquired by GSK), Calporta (acquired by Merck), and Synthorx (acquired by Sanofi). Avalon BioVentures concentrates on biotechnology and life sciences, investing primarily in companies that are developing groundbreaking therapies for unmet clinical needs. Geographically, the firm focuses on the U.S., leveraging its strong presence in San Diego’s vibrant biotech hub. The firm’s strategy involves more than just capital; it includes active partnership through their integrated life science accelerator, providing essential resources, operational support, and strategic guidance from day one. Avalon BioVentures typically leads investment rounds, with average checks ranging from early seed funding to larger Series A investments. Key team members include Jay Lichter, Ph.D., an experienced biotech executive, Sanford J. Madigan, Ph.D., who has a rich background in corporate financing and business development, and Sergio G. Duron, Ph.D., known for his extensive experience in drug discovery and preclinical development. These leaders, among others, bring a combination of scientific expertise and entrepreneurial acumen, ensuring a hands-on approach to building successful biotech companies. Startups seeking investment should approach Avalon BioVentures with a clear vision for innovation in life sciences and a readiness to engage in a collaborative, entrepreneurial partnership.

Avalon Ventures is a San Diego-based venture capital firm with a focus on early-stage investments, particularly in life sciences and information technology. Founded in 1983, Avalon has a reputation for being one of the pioneering VCs in its field, actively seeking out companies with disruptive technologies and strong potential for market impact. Avalon tends to invest during the seed and Series A stages, with a preference for being the first institutional investor in many of its portfolio companies. The firm has made over 157 investments, with notable portfolio companies like Synthorx, Jnana Therapeutics, and Averon. Avalon is also known for its partnership with GlaxoSmithKline (GSK), which has helped launch several life science ventures through its joint funding efforts. Their long-term approach has led to several successful exits, including IPOs from companies like Kaltura and Janux Therapeutics. Avalon’s investment strategy revolves around identifying and nurturing innovative companies that align with their thesis-driven approach, focusing on emerging trends in both healthcare and tech sectors. The firm operates out of its offices in La Jolla, California, and Cambridge, Massachusetts, allowing it to maintain a strong presence on both coasts of the U.S. and globally.

Avestria Ventures is a California-based venture capital firm founded in 2018 by veteran life science executives Linda Greub and Corinne Nevinny. Operating from the San Francisco Bay Area and Beverly Hills, the firm invests in early-stage women's health and life science companies, with a primary focus on women-led founding teams — a market segment that has historically been underfunded relative to its commercial and clinical potential. Avestria leads rounds with typical checks of $500,000 to $5 million across pre-seed through Series A stages. The firm has made 43 investments and achieved notable portfolio exits, including Alydia Health's acquisition by Organon for up to $240 million and Uqora's acquisition by Pharmavite. Avestria closed Fund I in 2021 and has continued deploying through Fund II. With a team of 20 including 6 partners, the firm brings deep life sciences industry expertise across regulatory, clinical, and commercial pathways that matter most for health companies navigating product development to market. Avestria is one of the few dedicated venture funds at the intersection of women's health innovation and female-founded companies — a dual focus that reflects both a market conviction and an investment philosophy. The firm's large advisory network provides portfolio companies with the domain-specific guidance needed to navigate FDA processes, clinical trial design, and pharma partnership negotiations. Greub and Nevinny's combined decades of life science industry experience give Avestria a credibility advantage with founders, corporates, and co-investors that sector-agnostic funds cannot easily replicate.

Avila VC is a Miami, Florida-based venture capital firm founded in 2022 by Patricia Wexler. The firm invests at the intersection of bits and atoms — companies that combine software and physical sciences to rebuild foundational industries for abundance, sustainability, and human flourishing. Target sectors include climate technology, human health, agtech, biotech, and neural technologies, with a global investment footprint spanning the United States, United Kingdom, Australia, Israel, Brazil, and Mexico. Avila invests at pre-seed, seed, and Series A stages, with checks ranging from $250,000 to $5 million across 12 portfolio companies. Notable investments include Aionics in computational chemistry, Dig Energy in geothermal technology, and Realta Fusion in fusion energy — companies working on fundamental physical-world problems where computational approaches create scientific leverage. The portfolio reflects a conviction that the most consequential companies of the next decade will operate at the boundary between deep science and scalable software. Avila VC distinguishes itself through its focus on deep technology companies transforming foundational industries such as energy, food, and healthcare — rather than incremental software improvements. Patricia Wexler's investment thesis holds that climate, health, and abundance challenges require solutions rooted in physical science, not just digital abstraction. The firm's global geography reflects an understanding that the best founders tackling these problems are distributed worldwide, and that access to capital should not be constrained by proximity to traditional technology hubs.

Avoro Capital Advisors is a global life sciences investment firm based in New York, known for its strategic focus on biotechnology, life sciences, and specialty therapeutics. Founded as venBio Select Advisor, the firm has been instrumental in supporting emerging biotech companies that are driving innovation in the treatment of unmet medical needs. Avoro's investment strategy emphasizes identifying unique or undervalued opportunities in the market, often participating in both public and private investments across the biotech landscape. The firm’s portfolio includes a range of prominent companies such as Immunomedics (acquired by Gilead in 2020), MyoKardia (acquired by Bristol Myers Squibb), and Mirati Therapeutics, among others. Avoro is recognized for its hands-on approach, offering not just financial backing but also deep intellectual support to foster scientific breakthroughs. Avoro Ventures, a venture capital arm of the firm, extends this mission by focusing on early-stage investments in the drug discovery and healthcare tools sectors. The team is led by Managing Partner and Portfolio Manager Behzad Aghazadeh, who is highly regarded in the industry for his expertise in biopharmaceutical investments. With a comprehensive approach that includes rigorous risk management and a strong focus on innovation, Avoro Capital continues to be a key player in advancing biopharmaceutical developments.

Awesome People Ventures is an early-stage venture capital firm that focuses on investing in Web3 and other transformative technologies that are poised to reshape how we live and work. Founded by Julia Lipton, a seasoned entrepreneur and investor, the fund is dedicated to supporting founders who are not only innovative but also committed to building companies with integrity, inclusivity, and long-term impact. The firm primarily invests in startups at the pre-seed and seed stages, with a particular emphasis on those operating in the Web3 space—a sector that encompasses blockchain, decentralized finance (DeFi), and other emerging technologies that enable new forms of digital ownership, governance, and value exchange. Awesome People Ventures is driven by the belief that Web3 represents a pivotal technological and cultural shift, with the potential to fundamentally alter various industries and create more equitable systems. In addition to providing capital, Awesome People Ventures offers hands-on growth support, including strategic guidance, mentorship, and access to an exclusive talent network. This holistic approach ensures that the startups in their portfolio have the resources they need to navigate the challenges of early-stage growth and scale successfully. The firm is backed by a group of high-profile investors, including Marc Andreessen and Chris Dixon, who are known for their expertise in the crypto and technology sectors. Awesome People Ventures is committed to backing a diverse range of founders and ideas, aiming to foster innovation that leads to a more inclusive and equitable future.

Axelys is a dynamic technology transfer and innovation organization based in Quebec, dedicated to advancing the commercialization of public research. Launched in 2021, it was formed to centralize and streamline efforts from three prior institutions—Aligo Innovation, Sovar, and Univalor—creating a unified approach to foster innovation across the province. Funded by the Quebec Ministry of Economic Development, Axelys partners closely with universities, hospitals, and research centers, helping to transform academic discoveries into market-ready solutions. Axelys focuses on sectors like biotechnology, healthcare, green technologies, and other high-impact areas, working to develop intellectual property assets and create startups from promising research. Through comprehensive support that includes consulting, business development, and intellectual property management, Axelys helps researchers navigate the commercialization journey, turning innovative ideas into sustainable businesses. The organization’s mission emphasizes building stronger connections between academia and industry, with the goal of making Quebec a leader in innovation and economic growth. Leading the charge is CEO Paule De Blois, who brings over 20 years of experience in managing innovation projects. Her leadership focuses on fostering a collaborative ecosystem that bridges scientific research with entrepreneurial ambitions. Axelys is backed by a diverse team and a start-up committee led by Chief Innovator Luc Sirois, which includes key figures from academia and industry. Together, they aim to increase Quebec's competitiveness, boost the creation of high-quality jobs, and contribute to economic and social prosperity by harnessing the full potential of public research.

Axial VC is a San Francisco-based venture capital firm, founded in 2019 by Joshua Elkington. The fund is focused on early-stage investments in the biotechnology sector, with a particular emphasis on innovative therapeutics and healthcare technologies. Axial has a strong track record of backing cutting-edge startups, with notable investments including CHARM Therapeutics, which leverages AI in biotechnology, and Replay, a leader in gene therapy. Geographically, Axial’s portfolio spans across key biotech hubs in the U.S. and Europe, such as San Francisco, San Diego, and London. The fund is known for participating in sizeable funding rounds, with an average check size of around $19M, although it does not typically lead these rounds. Instead, Axial often co-invests alongside prominent firms like Khosla Ventures, General Catalyst, and OrbiMed, ensuring a collaborative approach to scaling its portfolio companies. Axial’s strategy is heavily centered on identifying transformative technologies at the intersection of biology and data science. The fund actively seeks out startups with strong scientific foundations and the potential to disrupt traditional healthcare paradigms. For entrepreneurs looking to connect with Axial, the firm values a clear demonstration of technical innovation and market potential. The team, based primarily in San Francisco, is hands-on, providing not just capital but also strategic guidance to help startups navigate the complexities of early-stage growth.

Axon Partners Group, founded in 2006 and headquartered in Madrid, Spain, is a global investment and consulting firm specializing in technology and innovation. The firm operates across multiple investment strategies, including direct venture capital investments, funds of funds, and growth equity. Axon has a strong presence in Europe, Israel, and the U.S., and it focuses on sectors such as digital, life sciences, deep tech, and sustainable technology. Axon Partners Group has made numerous notable investments. For instance, they invested in ISR, a Spanish technology company specializing in artificial vision systems for quality control in industry. ISR's Specular Vision® technology addresses complex inspection needs for transparent and reflective surfaces in various sectors like automotive and metallurgy. Axon's investment aims to support ISR's international expansion and strengthen its position as a leader in machine vision technology. Other significant investments include Finizens, a wealth management firm offering digital robo-advisory services, and Holaluz, an independent energy company in Spain providing green power and gas to businesses and households. Additionally, Axon has supported companies like Nextmol, which focuses on accelerating the design of new chemicals through molecular modeling and AI, and Glamping Hub, a global platform for unique outdoor accommodations. Axon's investment approach combines financial support with strategic consulting to help portfolio companies scale and innovate. They are committed to sustainability and investing in technologies that drive the transition to a sustainable world.

B Capital Group, founded in 2015 by Eduardo Saverin, Raj Ganguly, and Howard Morgan, is a global multi-stage investment firm. The firm focuses on investing in technology, healthcare, and climate sectors, supporting companies from seed to late-stage growth. With $7+ billion in assets under management, B Capital operates out of eight global locations, including New York, San Francisco, Los Angeles, Singapore, Beijing, and Hong Kong. B Capital's portfolio includes over 160 companies. Notable investments are in firms like Icertis, an AI-powered contract lifecycle management platform; Synack, a crowdsourced cybersecurity testing platform; and Khatabook, a digital bookkeeping solution for small businesses. These investments reflect B Capital's focus on transformative technologies that have the potential to reshape industries. The firm leverages its strategic partnership with Boston Consulting Group (BCG) to provide portfolio companies with expert advice, operational support, and strategic connections, helping them scale efficiently and effectively across global markets. B Capital's recent initiatives include the closure of their third growth fund series at $2.1 billion, emphasizing their commitment to supporting high-growth startups in the enterprise, fintech, and healthcare tech sectors. B Capital's investment approach is characterized by value-add investing, where they offer comprehensive support throughout the business development lifecycle. This includes advisory services on entering new markets, talent acquisition, and strategic business development, ensuring their portfolio companies achieve sustainable growth and success.

b2venture is a European venture capital firm, originally known as btov Partners, focusing on early-stage investments in both digital and industrial technologies. Founded in 2000, the firm invests in high-growth companies across sectors like AI, fintech, biotech, deep tech, and insurtech. With a network of angel investors, b2venture offers not just capital but also strategic support and mentorship to help scale innovative startups. The firm typically invests between €250,000 and €3.5 million, primarily at the Seed and Series A stages, but also supports follow-on rounds. Their portfolio spans a diverse range of industries, including companies like DeepL, Raisin, and Marvel Fusion. b2venture is particularly keen on businesses that demonstrate strong technological potential and scalability across European and global markets. Headquartered in Saint Gallen, Switzerland, with additional offices in Berlin and Luxembourg, b2venture manages over €100 million annually. They leverage their strong community of co-investors and partners to drive innovation, aiming for long-term growth in their portfolio companies.

B37 Ventures is a venture capital firm based in San Francisco, California, founded in 2013. The firm operates on a unique platform that facilitates the exchange of innovation and scale between startups and multinational corporations. This platform allows B37 Ventures to validate product-market fit and curate scalability through the global reach of its diverse corporate investors. The firm focuses on investing in transformative companies across various industries, including industrial and manufacturing, business services, consumer products, and life sciences and healthcare​ (VC Fund List)​. B37 Ventures typically engages with businesses at early stages, providing operational support, strategic guidance, and access to a vast network of corporate partners. B37 Ventures has a notable portfolio that includes companies like Dexterity, an AI-based automation tool and robotics company for managing warehouses, which became a unicorn in 2021. Other recent investments include Ansa, Windfall Bio, and Metaplane, emphasizing their active participation in funding innovative technologies. The team at B37 Ventures includes Managing Partners Rodrigo Sanchez Servitje and David Hite, among others, who bring extensive experience and a hands-on approach to supporting their portfolio companies. For startups looking to partner with B37 Ventures, highlighting strong innovation potential and the ability to scale within their focused industries can be advantageous. The firm's strategic connections and industry expertise provide significant value to their portfolio companies.

Babel Ventures is a Silicon Valley-based venture capital firm that focuses on early-stage investments, particularly in biotech and deep tech. The firm aims to support high-impact founders who are tackling some of humanity's most pressing challenges. Since its inception, Babel Ventures has positioned itself as a leader in consumer biotech, backing startups that have the potential to drive significant changes in consumer behavior and systemic improvements. The firm's team, led by Ryan Bethencourt and Ba Minuzzi, among others, is known for its multidisciplinary approach, blending expertise in science, technology, and entrepreneurship. This allows them to partner effectively with revolutionary startups that are pioneering innovative solutions across various sectors. Babel Ventures launched its first fund, Babel Fund I, and continues to develop new funds and special purpose vehicles (SPVs) to support visionary entrepreneurs. Their portfolio includes companies that are making strides in fields like healthcare, sustainability, and consumer products, all underpinned by cutting-edge biotech and deep tech innovations​.

Backed VC is a human-centric venture capital firm based in London, known for its early-stage investments across Europe. Since its inception, Backed VC has supported over 80 companies, including notable names like FabricNano, Sky Mavis, Hoxton Farms, and Ruka Hair. The firm typically invests at the Seed stage, with average ticket sizes ranging from €500K to €2.5M. Backed VC’s investment strategy focuses on fostering strong relationships with founders, viewing them as the most crucial asset of any company. They emphasize a collaborative approach, providing extensive support through their proprietary Seed to Series A Founder Development Platform, which offers masterclasses, tools, and services to help founders navigate the complexities of scaling their businesses. This platform assists with everything from hiring to preparing for subsequent funding rounds, emphasizing leadership development and mental health support. The firm operates with a community-centric ethos, creating a robust intra-portfolio network where founders can share experiences and resources. This includes workshops, the BACKED Buddy Programme, and informal gatherings that facilitate deeper connections among portfolio companies.

Backend Capital is an investment powerhouse focused on nurturing the next wave of innovative startups. Notable investments include Secureframe, Trove, and other high-potential tech ventures. This fund zeroes in on companies that are at the intersection of software engineering and data-driven business models, emphasizing industries like cybersecurity and AI. Geographically, Backend Capital predominantly targets startups in North America, with a keen eye on burgeoning tech hubs. The fund’s strategy revolves around backing visionary founders early, typically leading seed rounds with an average check size that varies based on the company’s potential and needs. Backend Capital's investment philosophy is built on deep engagement, often taking an active role in guiding startups through their growth journey. They prefer to be approached through warm introductions, valuing strong referrals within the tech community. The fund's funnel is curated through a mix of proactive outreach and strategic networking at key industry events. The team is spearheaded by industry veterans like Matt and Eric, who bring a wealth of experience from their respective backgrounds in high-stakes venture capital and hands-on startup development. Their unique approach combines rigorous technical evaluation with a genuine passion for empowering entrepreneurs. Backend Capital stands out by not just investing capital but also committing to the long-term success of its portfolio companies, making it a formidable player in the venture capital landscape.

BackingMinds is a Swedish venture capital firm founded in 2016 with a mission to support startup entrepreneurs who are typically overlooked by traditional VC networks. The firm focuses on identifying and investing in high-potential founders from underrepresented backgrounds, particularly those outside major tech hubs or those not fitting the conventional startup mold. Currently, BackingMinds is investing from its second fund, which has raised around €50 million. The firm has a diversified portfolio, including companies like CemVision in building products, TrusTrace in supply chain traceability, and Transfer Galaxy, a digital remittance platform. These investments reflect BackingMinds' commitment to uncovering and nurturing talent in areas that are often missed by other investors. The team, led by founding partners Sara Wimmercranz and Susanne Najafi, is based in Stockholm and operates with a hands-on approach. They are particularly known for backing women and immigrant-led startups or businesses located outside Sweden's traditional tech ecosystem, including cities beyond Stockholm.

Bain Capital Ventures (BCV) is a prominent venture capital firm that focuses on investing in early to growth-stage companies across several key sectors including fintech, infrastructure software, application software/SaaS, and commerce. With over $10 billion in assets under management, BCV operates from offices in the Bay Area, New York City, and Boston. Notable investments in BCV’s portfolio include successful companies like DocuSign, LinkedIn, Redis Labs, Rapid7, and Bill.com. These investments highlight BCV’s ability to identify and support transformative companies across diverse industries. The firm typically invests in stages ranging from seed to growth equity, providing capital from $1 million to $100 million per investment​. BCV's investment strategy is deeply rooted in building strong partnerships with founders, offering targeted support from founding to IPO and beyond. Their team of seasoned professionals, including partners like Matt Harris, Merritt Hummer, and Scott Friend, bring a wealth of experience and industry expertise to help portfolio companies scale and succeed. For startups looking to engage with BCV, it is beneficial to demonstrate innovation and potential in key areas such as fintech, digital infrastructure, and commerce technology. BCV’s extensive network and hands-on approach can provide significant strategic advantages to growing companies.